no surprise there - not with Gerald Commissiong - illusion creator, serial diluter, hack, Stanford Univ. "Financial Engineer", twice failed wann-be CEO, and his Astoria Queens financial mafia - toxic spiral death convertible debt associates...
well this is all wrong - not with 3-Bil. OS and 2.7-Bil. already out on the street and 300-Mil. more left to dilute...
but you know what JoeyForkitBollo (anonymous multiple pizza delivery guy prankster and family personal info disseminator) ... I hope you and all the rest of the TOMDF emaciated shareholders are able to get this POS scam security back over $0.01 and salvage your "catastrophic" averaged down losses here as well - and the reason why I am wishing you and the rest here good fortune - is because I'm a good guy - and someone who got taken by Gerald myself with a breached agreement - and knows the truth about Gerald and his ilk....
As COVID ramps up this fall Tollovid sales are surely to increase as the cat is already out of the bag that they have a product that actually works in COVID and Long Covid according to their market research survey. If the company releases these COVID sales numbers with investors it’s going to give very good insight with respect to its future profitability. News that the company isn’t dead after all will give early investors at these lotto prices a very nice return.
THE PATENT NEWS
TOMDF just announced a Notice of Allowance for the composition of Tollovid and Tollovir. This patent news is as significant as the Axcella Therapeutics (NASDAQ: AXLA) patent news on Long Covid that moved the stock 300% higher. Todos has a lot of intellectual property related to their 3CL protease inhibitor.
News 
Market Data 
Discover 
